{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:45:25Z","timestamp":1786149925075,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA266402"],"award-info":[{"award-number":["5R01CA266402"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ygyno.2026.06.025","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:19:51Z","timestamp":1784067591000},"page":"178-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States"],"prefix":"10.1016","volume":"211","author":[{"given":"Claudia L.","family":"Seguin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Linton B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pari V.","family":"Pandharipande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ygyno.2026.06.025_bb0005","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness thresholds used by study authors, 1990-2021","volume":"329","author":"Neumann","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0010","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet], Surveillance Research Program, National Cancer Institute. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/ Accessed February 12, 2025."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.025_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2017.11.008","article-title":"Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence","volume":"148","author":"Champer","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.025_bb0020","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.06.025_bb0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/Gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.06.025_bb0030","series-title":"Real-World Use of Bevacizumab for Treatment of Advanced Ovarian Cancer among Elderly Women in the U.S. [Doctoral dissertation]","author":"Hildebrand","year":"2024"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0035","unstructured":"Avastin (Bevacizumab) Price, News Medical Life Sciences. n.d. https:\/\/www.news-medical.net\/health\/Avastin-(Bevacizumab)-Price.aspx Accessed July 14, 2023."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.025_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.5422","article-title":"Comparison of prices for commonly administered drugs in employer-sponsored insurance relative to Medicare","volume":"4","author":"Chang","year":"2023","journal-title":"JAMA Health Forum."},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.025_bb0045","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2010.32.1075","article-title":"At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis","volume":"29","author":"Cohn","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.025_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195134","article-title":"First- and second-line bevacizumab in ovarian cancer: a Belgian cost-utility analysis","volume":"13","author":"Neyt","year":"2018","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.ygyno.2026.06.025_bb0055","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1002\/cncr.28283","article-title":"Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer","volume":"119","author":"Barnett","year":"2013","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.025_bb0060","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jval.2016.01.013","article-title":"The cost-effectiveness of bevacizumab in advanced ovarian cancer using evidence from the ICON7 trial","volume":"19","author":"Hinde","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.025_bb0065","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2014.01.021","article-title":"Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer","volume":"132","author":"Mehta","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.025_bb0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s41669-017-0030-7","article-title":"Economic Evaluation of bevacizumab for treatment of platinum-resistant recurrent ovarian cancer in Canada","volume":"2","author":"Ball","year":"2018","journal-title":"Pharmacoecon Open."},{"key":"10.1016\/j.ygyno.2026.06.025_bb0075","unstructured":"Food and Drug Administration Biosimilar Product Information. n.d. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information Accessed February 1, 2026."},{"key":"10.1016\/j.ygyno.2026.06.025_bb0080","author":"Generics and Biosimilars Initiatives"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0085","unstructured":"FDA Biosimilars, n.d. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars Accessed March 1, 2023."},{"key":"10.1016\/j.ygyno.2026.06.025_bb0090","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0095","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0100","series-title":"Physician Fee Schedule Look-up Tool","author":"Centers for Medicare & Medicaid Services","year":"2026"},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.025_bb0110","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1055-9965.EPI-19-1534","article-title":"Medical care costs associated with cancer survivorship in the United States","volume":"29","author":"Mariotto","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ygyno.2026.06.025_bb0115","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0120","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0125","first-page":"1","article-title":"Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999-2000 through 2015-2016","volume":"122","author":"Fryar","year":"2018","journal-title":"Natl Health Stat Report."},{"issue":"9","key":"10.1016\/j.ygyno.2026.06.025_bb0130","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.21873\/anticanres.12834","article-title":"Prognostic value of serum creatinine levels in patients with epithelial ovarian cancer","volume":"38","author":"Lafleur","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2026.06.025_bb0135","author":"Centers for Medicare & Medicaid Services"},{"key":"10.1016\/j.ygyno.2026.06.025_bb0140","author":"U.S. Bureau of Labor Statistics"},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.025_bb0145","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:34:47Z","timestamp":1786149287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S0090825826020512"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}